Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies ; volume:3 ; number:1-2 ; day:28 ; month:8 ; year:2015 ; pages:47-68 ; date:12.2015
Rare Cancers and Therapy ; 3, Heft 1-2 (28.8.2015), 47-68, 12.2015
- Creator
-
Larsen, Jeremy T.
Kumar, Shaji
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40487-015-0009-4
- URN
-
urn:nbn:de:101:1-2411120900278.831693796139
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Larsen, Jeremy T.
- Kumar, Shaji
- SpringerLink (Online service)
Other Objects (12)
New therapies in multiple myeloma
Supply chain transformation : evolving with emerging business paradigms
Evolving therapeutic paradigms in ocular graft-versus-host disease
Estrogenic or antiestrogenic therapies for multiple myeloma?
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs
Emerging agents and regimens for multiple myeloma
CAR T therapies in multiple myeloma: unleashing the future
Chimeric antigen receptor T cell therapies for multiple myeloma
Evolving role of high dose stem cell therapy in multiple myeloma
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
New therapies in multiple myeloma
Supply chain transformation : evolving with emerging business paradigms
Evolving therapeutic paradigms in ocular graft-versus-host disease
Estrogenic or antiestrogenic therapies for multiple myeloma?
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs
Emerging agents and regimens for multiple myeloma
CAR T therapies in multiple myeloma: unleashing the future
Chimeric antigen receptor T cell therapies for multiple myeloma
Evolving role of high dose stem cell therapy in multiple myeloma
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
New therapies in multiple myeloma
Supply chain transformation : evolving with emerging business paradigms
Evolving therapeutic paradigms in ocular graft-versus-host disease
Estrogenic or antiestrogenic therapies for multiple myeloma?
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs
Emerging agents and regimens for multiple myeloma
CAR T therapies in multiple myeloma: unleashing the future
Chimeric antigen receptor T cell therapies for multiple myeloma
Evolving role of high dose stem cell therapy in multiple myeloma